Form 4 for INKT MiNK Therapeutics, Inc.
Accepted 2023-01-12 00:00:00 ET · period of report 2023-01-09 · accession 0000899243-23-001660 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-12 | 2023-01-09 | INKT | van Dijk Marcus Antonius | CSO | A - Grant | $2.32 | +51.6K | 51.6K | New | +$119.8K | |
| 2023-01-12 | 2023-01-09 | INKT | van Dijk Marcus Antonius | CSO | F - Tax | $2.32 | -24.3K | 27.4K | -47% | -$56.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-09 | A | A | 51,628 | $2.32 | 51,628 | D | — | — | (F1) Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023. (F2) $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date. |
| 2 | Common | Common Stock | 2023-01-09 | F | D | 24,265 | $2.32 | 27,363 | D | — | — | (F3) Represents payment of tax liability by withholding shares of common stock incident to the vesting of stock. |